Piper Jaffray analyst JP McKim noted that T1D Exchange, a nonprofit research organization, released its findings of a survey of Type 1 Diabetes patients. The survey results lead him to believe "there is plenty of growth just in the Type 1 market ahead" for Dexcom (DXCM), to be followed by the G7 launch, which will "help unlock the Type 2 market." The survey also points to "an unprecedented level of market share taking" by Tandem (TNDM) in the first 6 months of the year and was positive for Insulet (PODD) as well, McKim tells investors. He has Overweight ratings on all three stocks mentioned.

Leerink upgraded Tandem Diabetes to Outperform from Market Perform with a $45 price target.